Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.7K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.7K
Autophagic Cell Death01:18

Autophagic Cell Death

3.5K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Autophagy01:27

Autophagy

4.5K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same author

Efficient Syngas Photoproduction Enabled by Electronic Engineering of Co-Immobilized Imine COFs.

Angewandte Chemie (International ed. in English)·2026
Same author

Guiding AlphaFold to predict how Munc13-1 opens Syntaxin-1.

FEBS open bio·2026
Same author

Optimization of Antifungal 1,5-Diaryl-Pyrazole Acetyl-CoA Synthetase Inhibitors.

ACS omega·2026
Same author

Secretory autophagy mediates SLC16A3/MCT4-dependent lactate secretion to drive metastatic progression in triple-negative breast cancer.

Autophagy·2026
Same author

Selective degradation of TBK1 uncovers mechanistic insights into blocking ccRCC progression.

Cell chemical biology·2026

Related Experiment Video

Updated: Aug 28, 2025

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

997

Novel Bcl-2 Inhibitors Selectively Disrupt the Autophagy-Specific Bcl-2-Beclin 1 Protein-Protein Interaction.

Xiaonan Dong1, Qiren Liang1, Yun-Zu Pan1

  • 1University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.

ACS Medicinal Chemistry Letters
|September 15, 2022
PubMed
Summary

Researchers developed novel small molecules that selectively target Bcl-2, releasing autophagy-related Beclin 1 inhibition. This breakthrough offers a promising strategy for developing new autophagy-based therapeutics for various diseases.

More Related Videos

siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells
09:10

siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells

Published on: October 28, 2019

7.3K
Study of Protein-protein Interactions in Autophagy Research
14:08

Study of Protein-protein Interactions in Autophagy Research

Published on: September 9, 2017

9.2K

Related Experiment Videos

Last Updated: Aug 28, 2025

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

997
siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells
09:10

siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells

Published on: October 28, 2019

7.3K
Study of Protein-protein Interactions in Autophagy Research
14:08

Study of Protein-protein Interactions in Autophagy Research

Published on: September 9, 2017

9.2K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Autophagy is crucial for cellular homeostasis, metabolism, development, differentiation, and immunity.
  • Targeting autophagy offers therapeutic potential for diverse human diseases.
  • Lack of specific small molecule autophagy modulators hinders therapeutic development.

Purpose of the Study:

  • To develop selective small molecule modulators of autophagy.
  • To identify compounds that release Bcl-2-mediated inhibition of Beclin 1.
  • To investigate the disruption of protein-protein interactions in autophagy regulation.

Main Methods:

  • Structure-activity relationship studies on Bcl-2 inhibitor SW076956.
  • Development of a panel of small molecule compounds.
  • Nuclear Magnetic Resonance (NMR) analysis to confirm compound binding and interaction specificity.

Main Results:

  • Developed small molecules that selectively release Bcl-2-mediated inhibition of Beclin 1 at nanomolar concentrations.
  • Compound 35 directly binds Bcl-2 and inhibits the Bcl-2/Beclin 1 BH3 domain interaction.
  • No disruption of the Bcl-2/Bax BH3 interaction was observed, indicating selectivity.

Conclusions:

  • Targeting protein-protein interactions within the autophagy regulatory network is a viable therapeutic strategy.
  • Novel small molecules demonstrate potential for developing autophagy-based therapeutics.
  • Selective modulation of Bcl-2 offers a promising avenue for disease treatment.